A pilot study to determine the effect of tazarotene gel 0.1% on steroid‐induced epidermal atrophy

No abstract is available for this paper.

• Publication year

  2001

• Venue

  International Journal of Dermatology

• Publication date

  2001-07-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1046/j.1365-4362.2001.01234.xPMID 11679006
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Investigator‐masked comparison of tazarotene gel q.d. plus mometasone furoate cream q.d. vs. mometasone furoate cream b.i.d. in the treatment of plaque psoriasis

  2001cited by this paper
• Photodamage pilot study: a double-blind, vehicle-controlled study to assess the efficacy and safety of tazarotene 0.1% gel.

  2000cited by this paper
• Combination therapy with tazarotene plus a topical corticosteroid for the treatment of plaque psoriasis

  1999cited by this paper
• Frequency of application of topical corticosteroids: an overview

  1998cited by this paper
• Tazarotene in combination with topical corticosteroids.

  1998cited by this paper
• Corticosteroid skin atrophogenicity: assessment methods

  1998cited by this paper
• Assessment of the atrophogenicity of corticosteroids to human skin using non‐invasive methods

  1998cited by this paper
• Tazarotene 0.1% gel plus corticosteroid cream in the treatment of plaque psoriasis.

  1997cited by this paper
• Echographic assessment of corticosteroid‐induced skin‐thinning, including echogenicity measurement

  1996cited by this paper
• Topical Glucocorticoids with Improved Risk-Benefit Ratio

  1996cited by this paper
• Concurrent application of tretinoin (retinoic acid) partially protects against corticosteroid‐induced epidermal atrophy

  1996cited by this paper
• A new method to measure type I and III collagen synthesis in human skin in vivo: demonstration of decreased collagen synthesis after topical glucocorticoid treatment.

  1992cited by this paper
• Topical all-trans-retinoic acid prevents corticosteroid-induced skin atrophy without abrogating the anti-inflammatory effect.

  1989cited by this paper
• Optical profilometry: an objective method for quantification of facial wrinkles.

  1989cited by this paper
• Corticosteroid atrophy in human skin. A study by light, scanning, and transmission electron microscopy.

  1983cited by this paper

• Fixed-Combination Halobetasol Propionate and Tazarotene in the Treatment of Psoriasis: Narrative Review of Mechanisms of Action and Therapeutic Benefits

  2021cites this paper
• Long COVID in the skin: a registry analysis of COVID-19 dermatological duration

  2021cites this paper
• Long‐term safety and efficacy of a fixed‐combination halobetasol propionate 0.01%/tazarotene 0.045% lotion in moderate‐to‐severe plaque psoriasis: phase 3 open‐label study

  2021cites this paper
• Fixed combination of tazarotene and betamethasone dipropionate for treatment of psoriasis vulgaris: The result of a phase 3, multicenter, randomized controlled trial

  2020cites this paper
• Topical Therapy II: Retinoids, Immunomodulators, and Others

  2020cites this paper
• Safety considerations with combination therapies for psoriasis

  2020cites this paper
• Optimized formulation for topical application of a fixed combination halobetasol/tazarotene lotion using polymeric emulsion technology

  2019cites this paper
• Halobetasol 0.01%/Tazarotene 0.045% Fixed-combination Lotion in the Treatment of Plaque Psoriasis: Sensitization and Irritation Potential.

  2019cites this paper
• Safety and Efficacy of a Halobetasol 0.01%/Tazarotene 0.045% Fixed Combination Lotion in the Treatment of Moderate-to-severe Plaque Psoriasis: A Comparison with Halobetasol Propionate 0.05% Cream.

  2018cites this paper
• Safety and efficacy of a fixed combination of halobetasol and tazarotene in the treatment of moderate‐to‐severe plaque psoriasis: Results of 2 phase 3 randomized controlled trials

  2018cites this paper
• Running title: SKIN TOXICITIES FROM TRANSPLANT MEDICATIONS Abbreviations: ATG – Antithymocyte globulin AZA – Azathioprine MMF – Mycophenolate mofetil SOTR – Solid organ transplant recipient

  2017cites this paper
• Cutaneous Toxicities From Transplantation‐Related Medications

  2017cites this paper
• The American Society of Transplantation Consensus Conference on the Use of Hepatitis C Viremic Donors in Solid Organ Transplantation

  2017cites this paper
• A Phase 2, Multicenter, Double-Blind, Randomized, Vehicle Controlled Clinical Study to Assess the Safety and Efficacy of a Halobetasol/Tazarotene Fixed Combination in the Treatment of Plaque Psoriasis.

  2017cites this paper
• Topical Corticosteroid-Induced Skin Atrophy: A Comprehensive Review

  2015cites this paper
• Preventive Effects of Multi-Lamellar Emulsion on Low Potency Topical Steroid Induced Local Adverse Effect

  2013cites this paper
• Efficacy and safety of combinations of first‐line topical treatments in chronic plaque psoriasis: a systematic literature review

  2013cites this paper
• Mechanisms of Action of Topical Corticosteroids in Psoriasis

  2012cites this paper
• Pseudoceramide-Containing Physiological Lipid Mixture Reduces Adverse Effects of Topical Steroids

  2011cites this paper
• Factors impacting the combination of topical corticosteroid therapies for psoriasis: perspectives from the international psoriasis council

  2011cites this paper
• Topical corticosteroids in psoriasis: strategies for improving safety

  2010cites this paper
• Topical Treatment of Mild to Moderate Psoriasis

  2010cites this paper
• PHOTODYNAMIC THERAPY AND SELECTED OFF-LABEL USES

  2010cites this paper
• Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 3. Guidelines of care for the management and treatment of psoriasis with topical therapies.

  2009cites this paper
• Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics.

  2008cites this paper
• Overview of Dermatological Diseases

  2007cites this paper
• Using topical multimodal strategies for patients with psoriasis.

  2007cites this paper
• Compatibility of topical therapies for psoriasis: challenges and innovations.

  2007cites this paper
• Receptor-Selective Retinoids for Psoriasis

  2006cites this paper
• Effects of a multilamellar emulsion on glucocorticoid‐induced epidermal atrophy and barrier impairment

  2006cites this paper
• Topical Tazarotene

  2005cites this paper
• Tratamientos tópicos de la psoriasis: actualización Topical treatment of psoriasis: An update

  2005cites this paper
• Topical therapies for psoriasis: evidence-based review.

  2005cites this paper
• Psoriasis treatment: traditional therapy

  2005cites this paper
• Review of therapy of psoriasis: the prebiologic armamentarium.

  2004cites this paper
• Evidence-Based Review of Topical Treatments for Psoriasis

  2004cites this paper
• Therapy treatment options for psoriasis: topical and systemic

  2004cites this paper
• Tazarotene: Therapeutic Strategies in the Treatment of Psoriasis, Acne and Photoaging

  2004cites this paper
• Changing paradigms in dermatology: nuclear hormone receptors.

  2003cites this paper
• The Topical Treatment of Psoriasis

  2003cites this paper
• The efficacy of topical tazarotene monotherapy and combination therapies in psoriasis

  2003cites this paper
• Drug Interactions in Psoriasis: The Pros and Cons of Combining Topical Psoriasis Therapies

  2002cites this paper
• Treatment of psoriasis. Part 1. Topical therapy and phototherapy.

  2001cites this paper
• Investigator‐masked comparison of tazarotene gel q.d. plus mometasone furoate cream q.d. vs. mometasone furoate cream b.i.d. in the treatment of plaque psoriasis

  2001cites this paper
• Duration of improvement in psoriasis after treatment with tazarotene 0.1% gel plus clobetasol propionate 0.05% ointment: comparison of maintenance treatments

  2001cites this paper
• Strategies to optimize efficacy, duration of remission, and safety in the treatment of plaque psoriasis by using tazarotene in combination with a corticosteroid.

  2000cites this paper
• Tazarotene combination treatments in psoriasis.

  2000cites this paper